Banque Pictet & Cie Sa Crispr Therapeutics Ag Transaction History

Banque Pictet & Cie Sa

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$61.1 - $83.78 $2,749 - $3,770	-45 Reduced 0.35%	12,805 $837 Million
Q2 2022 Aug 08, 2022	SELL	$43.23 - $73.83 $3.57 Million - $6.1 Million	-82,578 Reduced 86.53%	12,850 $781,000
Q1 2022 May 04, 2022	BUY	$53.19 - $79.24 $33,296 - $49,604	626 Added 0.66%	95,428 $5.99 Million
Q4 2021 Feb 02, 2022	BUY	$70.09 - $111.29 $5.87 Million - $9.32 Million	83,783 Added 760.35%	94,802 $7.18 Million
Q3 2021 Nov 10, 2021	BUY	$110.2 - $156.64 $136,427 - $193,920	1,238 Added 12.66%	11,019 $1.23 Million
Q2 2021 Aug 12, 2021	BUY	$100.84 - $161.89 $301,914 - $484,698	2,994 Added 44.11%	9,781 $1.58 Million
Q1 2021 May 11, 2021	BUY	$110.72 - $210.04 $599,438 - $1.14 Million	5,414 Added 394.32%	6,787 $827,000
Q4 2020 Feb 10, 2021	BUY	$79.67 - $173.23 $109,386 - $237,844	1,373 New	1,373 $210,000

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.74B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Banque Pictet & Cie Sa, based on Form 13F filings with the SEC.

Stay updated on Banque Pictet & Cie Sa with notifications on news.